Clinical immunogenicity specificity assessments: A platform evaluation

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 629-635

  Peng, Kun ^a   Siradze, Ketevan ^a   Quarmby, Valerie ^a   Fischer, Saloumeh Kadkhodayan ^a  

^a GENENTECH INC   (United States)

Author keywords

Anti therapeutic antibody; Confirmatory assay; Digoxigenin; Electrochemiluminescence assay; Enzyme linked immunosorbent assay; Immunogenicity

Indexed keywords

BIOTIN; DIGOXIGENIN; MONOCLONAL ANTIBODY; RUTHENIUM; THERAPEUTIC X MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; PRIORITY JOURNAL;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; BIOTIN; DIGOXIGENIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUMINESCENT MEASUREMENTS; RUTHENIUM; SENSITIVITY AND SPECIFICITY;

EID: 78149495448     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.035     Document Type: Article

References (18)

1. Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1: Considering consequences of the immune response to a protein. BioPharm Int. 2004, 17:22-26.
2. Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 2: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int. 2004, 17:34-42.
3. Rosenberg A.S., Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 3: Effects of manufacturing changes on immunogenicity studies. BioPharm Int. 2005, 18:32-36.
4. Thorland E.C., Drost J.B., Lusher J.M., Warrier I., Shapiro A., Koerper M.A., Dimichele D., Westman J., Key N.S., Sommer S.S. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999, 5:101-105.
5. Hartung H.P., Polman C., Bertolotto A., Deisenhammer F., Giovannoni G., Havrdova E., Hemmer B., Hillert J., Kappos L., Kieseier B., Killestein J., Malcus C., Comabella M., Pachner A., Schellekens H., Sellebjerg F., Selmaj K., Sorensen P.S. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J. Neurol. 2007, 254:827-837.
6. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., Gupta S., Herzyk D., Hurst C., Ivens I., Kawabata T., Maier C., Mounho B., Rup B., Shankar G., Smith H.W., Thomas P., Wierda D. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 2009, 54:164-182.
7. EMEA Guidelines on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins 2007, EMEA.
8. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A.R. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1-9.
9. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
10. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharmaceut. Biomed. Anal. 2008, 48:1267-1281.
11. Swanson S.J., Chirmule N. Assessing specificity for immunogenicity assays. Bioanalysis 2009, 1:611-617.
12. Swanson S.J. Immunogenicity issues in the development of therapeutic proteins. Int. J. Pharm. Med. 2007, 21:207-216.
13. Stubenrauch K., Wessels U., Vogel R., Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal. Biochem. 2009, 390:189-196.
14. Liang M., Klakamp S.L., Funelas C., Lu H., Lam B., Herl C., Umble A., Drake A.W., Pak M., Ageyeva N., Pasumarthi R., Roskos L. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 2007, 5:1-8.
15. Engvall E., Perlman P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971, 8:871-874.
16. Moxness M., Tatarewicz S., Weeraratne D., Murakami N., Wullner D., Mytych D., Jawa V., Koren E., Swanson S. Immmunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 2005, 51:1983-1985.
17. R.M.C. Dawson, D.C. Elliott, W.H. Elliott, K.M. Jones, Data for Biochemical Research, Oxford Science Publications, Oxford Univ. Press, NY, 3rd ed., 1986, pp. 284-285.
18. Yohrling J. Ligand-binding assay: risk of using a platform supported by a single vendor. Bioanalysis 2009, 1:629-636.